Journal Title：Pharmacology Research & Perspectives

PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS

PR&P 由美國藥理學和實驗治療學會 (ASPET)、英國藥理學學會 (BPS) 和 Wiley 聯合出版。PR&P 是一份雙月刊的開放獲取期刊，出版各種類型的文章，包括：靶標驗證（表明假設不正確的臨床前論文或關于在早期臨床開發(fā)中失敗的藥物的論文）；藥物發(fā)現評論（導致成功治療藥物的策略、假設和數據）；轉化醫(yī)學前沿（針對未滿足的治療需求的藥物和靶標驗證）；藥理學假設（旨在為新假設提供信息的評論）；以及復制研究（反駁關鍵發(fā)現 [復制失敗] 的工作和驗證關鍵發(fā)現的工作）。PR&P 發(fā)表直接提交給期刊的論文以及 ASPET 和 BPS 期刊推薦的論文

Pharmacology Research & Perspectives創(chuàng)刊于2013年，由Wiley-Blackwell出版商出版，收稿方向涵蓋General Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業(yè)影響力一般，過審相對較易，如果您文章質量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 20 Weeks ，影響因子指數2.9，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。